Terns Pharmaceuticals, Inc. (TERN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $52.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Rich valuation.
Terns Pharmaceuticals is a clinical-stage oncology company developing TERN-701, an oral allosteric BCR-ABL1 inhibitor for CML in Phase 1/2 (CARDINAL trial). The company entered a merger agreement with Merck Sharp & Dohme LLC at $53/share in March 2026; the merger closed May 5,... Read more
Sell if holding. Engine safety override at $52.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Terns Pharmaceuticals, Inc.
Material events (past 30 days)
- May 5, 2026 HIGH Item 5.01: Merger with Merck Sharp & Dohme LLC completed May 5, 2026. Merger Sub merged with and into Terns; Terns surviving as a wholly-owned subsidiary of Merck. Shares delisted from Nasdaq.
Latest news
- 'Merck Starts Seven-Part High-Grade Bond Sale to Fund Terns Deal' - Bloomberg — benzinga May 18, 2026 negative
- Oppenheimer Downgrades Terns Pharmaceuticals to Perform, Removes Price Target $58 — benzinga Apr 27, 2026 negative
- Terns Pharmaceuticals Wins FDA Breakthrough Therapy Designation For TERN-701 In Resistant CML — benzinga Apr 27, 2026 positive
- Merck's Waiting Period Expires Under Hart-Scott-Rodino Antitrust Improvements Act To Acquire Terns Pharmaceuticals — benzinga Apr 24, 2026 positive
- Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges — benzinga Apr 22, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineTERN-70110-K Item 1A: 'Our business currently depends heavily on the successful development, marketing approval and commercialization of TERN-701'
Material Events(8-K, last 90d)
- 2026-05-05Item 5.01HIGHMerger with Merck Sharp & Dohme LLC completed May 5, 2026. Merger Sub merged with and into Terns; Terns surviving as a wholly-owned subsidiary of Merck. Shares delisted from Nasdaq.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $52.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $52.81. Score 4.5/10, moderate confidence.
Take-profit target: $51.92 (-1.9% upside). Prior stop was $52.81. Stop-loss: $52.81.
Concentration risk — Pipeline: TERN-701; Target reached (-14.9% upside); Quality below floor (1.6 < 4.0).
Terns Pharmaceuticals, Inc. trades at a P/E of N/A (forward -34.0). TrendMatrix value score: 3.0/10. Verdict: Sell.
17 analysts cover TERN with a consensus score of 3.5/5. Average price target: $53.
What does Terns Pharmaceuticals, Inc. do?Terns Pharmaceuticals is a clinical-stage oncology company developing TERN-701, an oral allosteric BCR-ABL1 inhibitor...
Terns Pharmaceuticals is a clinical-stage oncology company developing TERN-701, an oral allosteric BCR-ABL1 inhibitor for CML in Phase 1/2 (CARDINAL trial). The company entered a merger agreement with Merck Sharp & Dohme LLC at $53/share in March 2026; the merger closed May 5, 2026.